The use of novel agents in the treatment of relapsed and refractory multiple myeloma

[1]  H. Einsele,et al.  Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). , 2009, Blood.

[2]  M. Dawson,et al.  Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma , 2009, Clinical Cancer Research.

[3]  A. Belch,et al.  High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program , 2009, British journal of haematology.

[4]  P. L. Bergsagel,et al.  Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma , 2008 .

[5]  Michael L. Wang,et al.  Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) , 2008 .

[6]  M. Boccadoro,et al.  Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial , 2008 .

[7]  S. Jagannath,et al.  Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience , 2008 .

[8]  A. Jakubowiak,et al.  Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib , 2008 .

[9]  D. Esseltine,et al.  Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. , 2008 .

[10]  S. Jagannath,et al.  Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM) , 2008 .

[11]  C. Hofmeister,et al.  Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma , 2008 .

[12]  A. Jakubowiak,et al.  Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM) , 2008 .

[13]  B. Barlogie,et al.  First thalidomide clinical trial in multiple myeloma: a decade. , 2008, Blood.

[14]  E. Kastritis,et al.  Pathogenesis and treatment of renal failure in multiple myeloma , 2008, Leukemia.

[15]  J. Crowley,et al.  VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma , 2008, Leukemia.

[16]  M. Boccadoro,et al.  Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Boccadoro,et al.  Thalidomide for treatment of multiple myeloma: 10 years later. , 2008, Blood.

[18]  G. Stein,et al.  Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. , 2008, The Journal of clinical investigation.

[19]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[20]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[21]  Anthony Boral,et al.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.

[22]  G. Morgan,et al.  Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. , 2007, Blood.

[23]  A. Rapoport,et al.  Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature , 2007, Cancer.

[24]  O. Sezer,et al.  Bortezomib inhibits human osteoclastogenesis , 2007, Leukemia.

[25]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Varettoni,et al.  Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Berrebi,et al.  Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug , 2007, American journal of hematology.

[28]  G. Morgan,et al.  Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.

[29]  Joseph D Tariman,et al.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. , 2007, Blood.

[30]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[31]  E. Dees,et al.  Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin , 2007, Annals of Hematology.

[32]  H. Müller-Hermelink,et al.  STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival , 2007 .

[33]  D. Reece,et al.  Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. , 2006, Leukemia research.

[34]  S. Jagannath,et al.  Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. , 2006 .

[35]  A. Krishnan,et al.  A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM). , 2006 .

[36]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[37]  K. Anderson,et al.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.

[38]  T. Hideshima,et al.  Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma , 2006, Clinical Cancer Research.

[39]  A. Dispenzieri,et al.  Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. , 2006, Archives of dermatology.

[40]  L. Mileshkin,et al.  Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[42]  M. Drysdale,et al.  Targeting Hsp90 for the treatment of cancer. , 2006, Current opinion in drug discovery & development.

[43]  D. Esseltine,et al.  Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  N. Munshi,et al.  The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.

[45]  B. Grosbois,et al.  A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Oshimi,et al.  Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. , 2006, Blood.

[47]  H. Goldschmidt,et al.  A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma , 2006, British journal of haematology.

[48]  S. Alkan,et al.  Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma , 2006, Leukemia & lymphoma.

[49]  D. Esseltine,et al.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.

[50]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[51]  Hiroshi Yasui,et al.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. , 2005, Blood.

[52]  D. Esseltine,et al.  Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. , 2005, Blood.

[53]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[54]  M. Boccadoro,et al.  Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant , 2005, European journal of haematology.

[55]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[56]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[57]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Kyriakou,et al.  Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma , 2005, British journal of haematology.

[59]  D. Esseltine,et al.  Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. , 2005, Blood.

[60]  J. Zeldis,et al.  Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent ActimidTM (CC‐4047) and their relationship with venous thrombosis , 2005, European journal of haematology.

[61]  M. Dimopoulos,et al.  Adverse effects of thalidomide administration in patients with neoplastic diseases. , 2004, The American journal of medicine.

[62]  D. Esseltine,et al.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.

[63]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Dimopoulos,et al.  Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. , 2004, The hematology journal : the official journal of the European Haematology Association.

[65]  J. Miguel,et al.  The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma , 2004, Leukemia.

[66]  G. Juliusson,et al.  Early response predicts thalidomide efficiency in patients with advanced multiple myeloma * , 2004, British journal of haematology.

[67]  S. Alkan,et al.  Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma , 2004, British journal of haematology.

[68]  N. Munshi,et al.  Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. , 2004, Blood.

[69]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Cavenagh,et al.  An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. , 2003, Leukemia research.

[71]  Bart Barlogie,et al.  DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  L. Mileshkin,et al.  Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. , 2003, Blood.

[73]  H. Hirai,et al.  Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. , 2003, Blood.

[74]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[75]  A. Anagnostopoulos,et al.  Thalidomide and dexamethasone for resistant multiple myeloma , 2003, British journal of haematology.

[76]  N. Munshi,et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. , 2003, Blood.

[77]  S. Haggarty,et al.  Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. , 2003, Chemistry & biology.

[78]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[79]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[80]  M. Borad,et al.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  H. Goldschmidt,et al.  Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[84]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Lacombe,et al.  Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma , 2002, Oncogene.

[86]  M. Gobbi,et al.  Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. , 2002, Haematologica.

[87]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[88]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[89]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[90]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[91]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[92]  M. Dimopoulos,et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  C. Crews,et al.  The ubiquitin‐proteasome pathway and proteasome inhibitors , 2001, Medicinal research reviews.

[94]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[95]  A. Lichtenstein,et al.  The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. , 2000, Cancer research.

[96]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[97]  F. Giles,et al.  Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol , 2000, American journal of hematology.

[98]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[99]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[100]  R. Kyle,et al.  A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. , 1995, Leukemia.

[101]  L. Kalish,et al.  Phase III Study Comparing Vincristine, Doxorubicin (Adriamycin), and Dexamethasone (VAD) Chemotherapy with VAD Plus Recombinant Interferon Alfa‐2 in Refractory or Relapsed Multiple Myeloma: An Eastern Cooperative Oncology Group Study , 1995, American journal of clinical oncology.

[102]  D. Ribatti,et al.  Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.

[103]  J. Reilly,et al.  A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. , 1995, Leukemia & lymphoma.

[104]  M. Ranson,et al.  VAD chemotherapy as remission induction for multiple myeloma. , 1995, British Journal of Cancer.

[105]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[106]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[107]  H. Lokhorst,et al.  VAD chemotherapy for refractory multiple myeloma , 1989, British journal of haematology.

[108]  S. Jagannath,et al.  High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma , 1987 .

[109]  B. Durie,et al.  Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  B. Barlogie,et al.  High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.

[111]  Zander,et al.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.

[112]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[113]  B. Thiers.  Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study , 2009 .

[114]  J. Zeldis,et al.  RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. , 2008, Drug safety.

[115]  R. Wieser,et al.  Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion , 2007, Leukemia.

[116]  H. Müller-Hermelink,et al.  STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. , 2007, Blood.

[117]  P. Sonneveld,et al.  Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.

[118]  P. Galieni,et al.  Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. , 2006, Haematologica.

[119]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[120]  A. Dalgleish,et al.  Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.

[121]  W. M. Smit,et al.  Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas , 2005, Leukemia.

[122]  F. Andreoni,et al.  Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) , 2003 .

[123]  B. Grosbois,et al.  Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). , 2002, The hematology journal : the official journal of the European Haematology Association.

[124]  C. Allis,et al.  Histone acetyltransferases. , 2001, Annual review of biochemistry.

[125]  A. Palumbo,et al.  Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. , 2001, Haematologica.

[126]  A. Dmoszyńska,et al.  Thalidomide treatment of resistant or relapsed multiple myeloma patients. , 2001, Haematologica.